Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer.

Conclusions and Relevance: These results suggest that pre-SRT PSA level may be a prognostic biomarker for outcomes of antiandrogen treatment with SRT. In patients receiving late SRT (PSA>0.6 ng/mL, hormone therapy was associated with improved outcomes. In men receiving early SRT (PSA ≤0.6 ng/mL), long-term antiandrogen treatment was not associated with improved OS. Future randomized clinical trials are needed to determine hormonal therapy benefit in this population. Trial Registration: ClinicalTrials.gov Identifier: NCT00002874. PMID: 32215583 [PubMed - as supplied by publisher]
Source: Ann Oncol - Category: Cancer & Oncology Authors: Tags: JAMA Oncol Source Type: research

Related Links:

Conclusions: 68Ga-THP-PSMA PET/CT had a major clinical impact in patients with prostate cancer. Management plans changed in nearly one third of patients with primary untreated prostate cancer and in over half of patients with biochemical recurrence. These results are comparable with management change figures reported with other types of PSMA PET tracers. 68Ga-THP-PSMA was well tolerated. No patients experienced SAEs or discontinued the study due to AEs. These results together with the simple cold kit manufacturing process of 68Ga-THP-PSMA are promising for larger scale accessibility and serve as a basis for a multicentre p...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: GU - PSMA PET (Poster Session) Source Type: research
AbstractBackgroundWe investigated prognostic factors for biochemical recurrence (BCR) after robot-assisted radical prostatectomy (RARP) with extended pelvic lymph node (LN) dissection.MethodsWe included 173 patients who underwent RARP with extended pelvic LN dissection without neoadjuvant therapy at our hospital between October 2010 and April 2018. BCR was defined as prostate serum antigen (PSA) levels  ≥ 0.2 ng/mL; BCR-free survival rates were determined using Kaplan–Meier analysis. We used Cox regression analysis to evaluate effects of PSA and pathologic variables on BCR.ResultsMedian follow-u...
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
AbstractIncreasingly, studies have explored health-related quality-of-life (HRQOL) outcomes after robot-assisted radical prostatectomy (RARP). Nevertheless, no study has compared differences between anterior and posterior surgical approaches. The aim of this study is to assess differences of HRQOL following these two surgical approaches. From January 2012 to September 2017, 653 patients underwent RARP at our institution. We included patients who underwent operations by three experienced surgeons with interchangeability of role as console operator, and who could evaluate preoperatively the Expanded Prostate Cancer Index Com...
Source: Journal of Robotic Surgery - Category: Surgery Source Type: research
Abstract Cancer of the prostate are cancers in which most incidences are slow growing and in the U.S., a record of 1.2 million new cases of prostate cancer occurred in 2018. The rates of this type of cancer have been increasing in the developing nations. The risk factors for prostate cancer include age, family history, and obesity. It is believed that the rate of prostate cancer is correlated with the Western diet. Various advances in methods of radiotherapy have contributed to lowering morbidity. Therapy for hormone-refractory prostate cancer is making progress, for almost all men with metastases will proceed to ...
Source: Current Topics in Medicinal Chemistry - Category: Chemistry Authors: Tags: Curr Top Med Chem Source Type: research
Abstract For patients experiencing biochemical recurrence in the absence of distant metastasis, salvage radiotherapy (SRT) with or without androgen deprivation therapy (ADT) is currently the only possible curative treatment option. Prostate-specific antigen (PSA) monitoring and the selected use of SRT has some advantages when compared with adjuvant radiotherapy. The most important one is avoidance of a potential overtreatment of patients who would never have disease progression, even in the presence of high-risk pathological features. The identification of a specific PSA cut-off seems to be incorrect. In patients ...
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Tags: Clin Oncol (R Coll Radiol) Source Type: research
The aim of this study was to compare the cost-effectiveness and quality-adjusted life years (QALYs) of active monitoring (AM), radical prostatectomy (PR), and external-beam radiotherapy with neoadjuvant hormone therapy (RT) for localized prostate cancer. Microsimulations of radical prostatectomy, 3D-conformal radiotherapy, or active monitoring were performed using Medicare reimbursement schedules and clinical trial results for a target population of men aged 50–69 years with newly diagnosed localized prostate cancer (T1-T2, NX, M0) over a time horizon of 10 years. Quality-adjusted life years (QALYs) and costs were as...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
We present the case of a 69-year-old man with history of prostate carcinoma treated with prostatectomy and subsequently with external beam radiotherapy and hormone therapy because of biochemical recurrences. More than 10 years after the diagnosis, follow-up 99mTc-HDP bone scans and SPECT/CT images demonstrated an incidental diagnosis of osteoblastic pleural plaques that quickly evolve to mesothelioma. PET/CT achieved the definitive diagnosis by guiding the biopsy to the highest and most accessible focus of glucidic hypermetabolism. Our case report raises the association between prostate cancer patients treated with externa...
Source: Clinical Nuclear Medicine - Category: Nuclear Medicine Tags: Interesting Images Source Type: research
Conditions:   Prostate Cancer;   Chemotherapy Effect;   Hormone Sensitive Prostate Cancer;   Locally Advanced Prostate Carcinoma Interventions:   Drug: Neoadjuvant chemotherapy combined with hormone therapy;   Drug: Neoadjuvant hormone therapy;   Procedure: Radical Prostatectomy (RP)+ extended lymph node dissection Sponsor:   RenJi Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Brain | Cancer | Cancer & Oncology | Clinical Trials | Hormonal Therapy | Hormones | Neurology | Prostate Cancer | Prostatectomy | Study | Toxicology